Compare BBWI & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBWI | MMED |
|---|---|---|
| Founded | 1963 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.1B |
| IPO Year | 1994 | 2026 |
| Metric | BBWI | MMED |
|---|---|---|
| Price | $17.24 | $10.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $24.88 | $22.56 |
| AVG Volume (30 Days) | ★ 5.3M | 619.2K |
| Earning Date | 05-28-2026 | 06-03-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $7,291,000,000.00 | N/A |
| Revenue This Year | N/A | $15.99 |
| Revenue Next Year | $2.19 | $10.00 |
| P/E Ratio | $5.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.28 | $10.92 |
| 52 Week High | $34.29 | $17.86 |
| Indicator | BBWI | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 32.01 |
| Support Level | $17.01 | N/A |
| Resistance Level | $19.43 | $15.80 |
| Average True Range (ATR) | 0.85 | 0.71 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 2.74 | 8.78 |
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 4% of sales from international markets in fiscal 2025. For fiscal 2025, 77% of sales stemmed from the brick-and-mortar network (which was composed of more than 1,900 retail stores), similar to 2024 levels, as consumer shopping patterns remained normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like men's and lip.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.